Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription 20.10.2025 1 Am J Clin Nutr 1 Atherosclerosis 3 BMC Ophthalmol 1 BMJ 2 Diabet Med 1 Diabetes 4 Diabetes Care 20 Diabetes Obes Metab 4 Diabetologia 1 Eur J Endocrinol 4 J Clin Endocrinol Metab 3 J Diabetes Complications 1 J Nutr 1 JAMA 1 Metabolism 2 Nat Genet 1 Nutr Metab (Lond) 1 Obstet Gynecol 1 Ophthalmology 1 Pediatr Diabetes 3 PLoS One 1 Retina 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Nutr

1. CHISBERT M, Castell AL, Van Den Berghe L, Breyton AE, et al
   Optimizing glycemic variability in type 2 diabetes using simple dietary and culinary recommendations to modulate starch digestibility: a randomized controlled trial.
   Am J Clin Nutr. 2025 Oct 13:S0002-9165(25)00611.
   PubMed         Abstract available
   
   

   
   Atherosclerosis

2. ARNOLD N, Gossling A, Weimann J, Bay B, et al
   Occurrence of coronary events in the absence of traditional risk factors: Understanding residual risk.
   Atherosclerosis. 2025;409:120475.
   PubMed         Abstract available
   
   

   
   BMC Ophthalmol

3. WU L, Li H, Li J
   miR-106a-5p targets CREB1 to regulate the inflammatory response in diabetic retinopathy.
   BMC Ophthalmol. 2025;25:568.
   PubMed         Abstract available
   
   
4. WANG Q, Liu C, Yuan G
   Outcomes of two-stage phacoemulsification and pars plana vitrectomy for proliferative diabetic retinopathy with coexisting cataract: a comparative study.
   BMC Ophthalmol. 2025;25:570.
   PubMed         Abstract available
   
   
5. SONG X, Li L, Wang X, Zhang X, et al
   Intravitreal anti-vascular endothelial growth factor agents as an adjunct for proliferative diabetic retinopathy: a systematic review and meta-analysis.
   BMC Ophthalmol. 2025;25:578.
   PubMed         Abstract available
   
   

   
   BMJ

6. HONG B, Lee H, Jung K, Rhee SY, et al
   Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study.
   BMJ. 2025;391:e085196.
   PubMed         Abstract available
   
   

   
   Diabet Med

7. LAURENZI A, Edd SN, Adolfsson P, Di Piazza F, et al
   Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users.
   Diabet Med. 2025 Oct 13:e70161. doi: 10.1111/dme.70161.
   PubMed         Abstract available
   
   
8. LOMBARDI K, Paciente R, Coombs S, Hanna N, et al
   A randomised trial of a trauma-informed well-being program to promote mental health in adolescents with type 1 diabetes: Study protocol.
   Diabet Med. 2025 Oct 10:e70148. doi: 10.1111/dme.70148.
   PubMed         Abstract available
   
   

   
   Diabetes

9. CHEN W, Liu J, Zou Y, Lu F, et al
   O-GlcNAcylation Stabilizes NEK7 to Drive Podocyte Pyroptosis in Diabetic Kidney Disease.
   Diabetes. 2025 Oct 16:db250484. doi: 10.2337/db25-0484.
   PubMed         Abstract available
   
   

   
   Diabetes Care

10. YUAN G, Huo J, Liu Y, Liu Y, et al
    Successful Treatment of Diabetic Scleredema With Corticosteroids, Mycophenolate Mofetil, and UVA Therapy.
    Diabetes Care. 2025 Oct 14:dc252272. doi: 10.2337/dc25-2272.
    PubMed        
    
    
11. KNUPP J, Cardoso P, Young KG, McDonald TJ, et al
    Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and Biomarkers.
    Diabetes Care. 2025 Oct 14:dc251029. doi: 10.2337/dc25-1029.
    PubMed         Abstract available
    
    
12. HEDLUND E, Maziarz M, Lindahl T, Elding-Larsen H, et al
    Clinical Characteristics in Swedish Children With and Without Autoantibodies at the Time of Type 1 Diabetes Diagnosis.
    Diabetes Care. 2025 Oct 15:dc250840. doi: 10.2337/dc25-0840.
    PubMed         Abstract available
    
    
13. TWIG G, Simchoni M, Dym I, Vinograd A, et al
    Thyroid, Celiac, and Other Autoimmune Diseases and the Risk of Incident Type 1 Diabetes in Young Adulthood.
    Diabetes Care. 2025 Oct 15:dc251423. doi: 10.2337/dc25-1423.
    PubMed         Abstract available
    
    

    
    Diabetes Obes Metab

14. TESFAYE H, Paik JM, Wexler DJ, Hathaway JT, et al
    GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70200.
    PubMed         Abstract available
    
    
15. ZHOU H, Wang Y, Song X, Xu T, et al
    Independent and joint association of fat-to-muscle mass ratio and cardiorespiratory fitness with type 2 diabetes mellitus incidence: A prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70217.
    PubMed         Abstract available
    
    
16. KOUFAKIS T, Sarafidis P, Tsapas A, Doumas M, et al
    Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70212.
    PubMed        
    
    
17. WEINREICH AA, Bagger JI, Jorgensen JT, Kristensen PL, et al
    Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70208.
    PubMed        
    
    
18. NI J, Chen L, Su H, Cai J, et al
    Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70214.
    PubMed         Abstract available
    
    
19. HTOO PT, Tesfaye H, Schneeweiss S, Wexler DJ, et al
    Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70195.
    PubMed         Abstract available
    
    
20. ZAKY A, Nguyen LT, Shi Y, Hou M, et al
    The effect of sugarcane extract supplementation on glycemic control in a mouse model of type 1 diabetes.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70183.
    PubMed         Abstract available
    
    
21. YU M, Wang T, Xu C, Bi Y, et al
    Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70197.
    PubMed         Abstract available
    
    
22. GU W, Wu X, Zhang M, Wang X, et al
    Efficacy and safety of iGlarLixi versus IDegAsp by baseline beta-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70181.
    PubMed         Abstract available
    
    
23. SMOLDEREN KG, Mena-Hurtado C, Zhao Z, Michalak W, et al
    Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
    Diabetes Obes Metab. 2025;27:6691-6704.
    PubMed         Abstract available
    
    
24. SAIDI AN, Konings LAM, Dietvorst CAW, de Jong VD, et al
    Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.
    Diabetes Obes Metab. 2025;27:6624-6631.
    PubMed         Abstract available
    
    
25. TANG H, Lu Y, Zhang B, Zhou T, et al
    Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
    Diabetes Obes Metab. 2025;27:6527-6536.
    PubMed         Abstract available
    
    
26. HUA R, Yang A, Gao L, Chow E, et al
    Social determinants of health and progression to cardio-renal-metabolic multimorbidity and mortality in people with prediabetes: A prospective cohort study.
    Diabetes Obes Metab. 2025;27:6605-6614.
    PubMed         Abstract available
    
    
27. AZEGAMI T, Kaneko H, Okada A, Suzuki Y, et al
    Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study.
    Diabetes Obes Metab. 2025;27:6294-6303.
    PubMed         Abstract available
    
    
28. BRAMLAGE P, Vijayan A, Varghese TP, Melepurakkal Sadanandan D, et al
    Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2025;27:6254-6263.
    PubMed         Abstract available
    
    
29. GAO FM, Kishore K, Pandey D, Jahanabadi H, et al
    Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy.
    Diabetes Obes Metab. 2025;27:6367-6374.
    PubMed         Abstract available
    
    
30. CRUTCHLOW M, Liu J, Hernandez-Illas M, Zhang H, et al
    Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
    Diabetes Obes Metab. 2025;27:6264-6274.
    PubMed         Abstract available
    
    
31. WONG S, Le GH, Dri CE, Teopiz KM, et al
    Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.
    Diabetes Obes Metab. 2025;27:6105-6115.
    PubMed         Abstract available
    
    
32. WAN S, Yan H, Sun QY, Zhu JQ, et al
    Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70201.
    PubMed         Abstract available
    
    
33. DESHMUKH H, Wilmot EG, Ssemmondo E, Barnes D, et al
    Exploring the interaction between ethnicity, deprivation and the use of CGM on diabetes outcomes-A study from the Association of British Clinical Diabetologists.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70206.
    PubMed         Abstract available
    
    

    
    Diabetologia

34. VERCALSTEREN E, Karampatsi D, Neicu M, Romanitan MO, et al
    Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
    Diabetologia. 2025 Oct 15. doi: 10.1007/s00125-025-06567.
    PubMed         Abstract available
    
    
35. ZHU R, Guo J, Huttunen-Lenz M, Silvestre M, et al
    Long-term effects of dietary protein and carbohydrate quality on prediabetes remission: results from the PREVIEW randomised multinational diabetes prevention trial.
    Diabetologia. 2025 Oct 15. doi: 10.1007/s00125-025-06560.
    PubMed         Abstract available
    
    
36. FAGHER K, Eeg-Olofsson K, Arnqvist H, Bolinder J, et al
    Uric acid and future complications in young individuals with type 1 diabetes: results from the Diabetes Incidence Study in Sweden (DISS) and the National Diabetes Registry of Sweden (NDR).
    Diabetologia. 2025 Oct 14. doi: 10.1007/s00125-025-06561.
    PubMed         Abstract available
    
    
37. PERNG W, Shu S, Nathan DM, Luchsinger JA, et al
    Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes Study.
    Diabetologia. 2025 Oct 11. doi: 10.1007/s00125-025-06571.
    PubMed         Abstract available
    
    

    
    Eur J Endocrinol

38. MATHIEU C, Meireles M, Pagotto U, Wabitsch M, et al
    EndoCompass project: research roadmap for diabetes, obesity, and metabolism.
    Eur J Endocrinol. 2025;193.
    PubMed         Abstract available
    
    

    
    J Clin Endocrinol Metab

39. KANINA A, Stener-Victorin E, Butwicka A, Oberg AS, et al
    Adverse cardiometabolic outcomes in men with sisters with polycystic ovary syndrome.
    J Clin Endocrinol Metab. 2025 Feb 27:dgaf121. doi: 10.1210.
    PubMed         Abstract available
    
    
40. THANARAJ TA, Abu-Farha M, Albatineh AN, Channanath A, et al
    Effect of Ethnicity on the Relationship Between Telomere Length and Metabolic Markers in Kuwait.
    J Clin Endocrinol Metab. 2025;110:e3656-e3664.
    PubMed         Abstract available
    
    
41. SOTO-MOTA A, Carrillo-Larco R, Gregg E, Rojas-Martinez R, et al
    Clinical Heterogeneity and Transitions of Obesity in Mexico. A Longitudinal Analysis of Multiple Representative National Surveys.
    J Clin Endocrinol Metab. 2025 Mar 11:dgaf158. doi: 10.1210.
    PubMed         Abstract available
    
    
42. LINGVAY I, Bache JK, Desouza CV, Fragao-Marques M, et al
    Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.
    J Clin Endocrinol Metab. 2025;110:e3596-e3606.
    PubMed         Abstract available
    
    

    
    J Diabetes Complications

43. ANGELOPOULOS N, Livadas S, Androulakis I, Petkova V, et al
    Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.
    J Diabetes Complications. 2025;39:109181.
    PubMed         Abstract available
    
    
44. BANERJEE S, Khubchandani J, Gonzales-Lagos R
    Diabetes, anxiety, and mortality risk among middle and older-aged Americans.
    J Diabetes Complications. 2025;39:109194.
    PubMed         Abstract available
    
    
45. ZHOU Q, Yang H, Xie XS, Wang RD, et al
    Gestational diabetes mellitus and the subsequent risk of chronic kidney disease: A systematic review and meta-analysis.
    J Diabetes Complications. 2025;39:109197.
    PubMed         Abstract available
    
    

    
    J Nutr

46. KASAHARA Y, Yoshida C, Kimura Y, Saito M, et al
    Maternal high-fat diet alters fetal autonomic activity independently of leptin receptor genotype in high-risk mouse models of type 2 diabetes mellitus.
    J Nutr. 2025 Oct 9:S0022-3166(25)00613-3. doi: 10.1016/j.tjnut.2025.
    PubMed         Abstract available
    
    

    
    JAMA

47. KRUGER N, Schneeweiss S, Fuse K, Matseyko S, et al
    Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
    JAMA. 2025;334:1255-1266.
    PubMed         Abstract available
    
    

    
    Metabolism

48. ASHLAW EF, Elfers CT, Chichura KS, Miranda IC, et al
    A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.
    Metabolism. 2025 Oct 13:156414. doi: 10.1016/j.metabol.2025.156414.
    PubMed         Abstract available
    
    

    
    Nat Genet

49. YANG Z, Pajuste FD, Zguro K, Cheng Y, et al
    Limited overlap between genetic effects on disease susceptibility and disease survival.
    Nat Genet. 2025;57:2418-2426.
    PubMed         Abstract available
    
    
50. ZHAO Y, Lockhart S, Liu J, Li X, et al
    Population-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health.
    Nat Genet. 2025;57:2436-2444.
    PubMed         Abstract available
    
    

    
    Nutr Metab (Lond)

51. RASAEI N, Bahadoran Z, Mirmiran P, Azizi F, et al
    Investigation of the association between total dietary calcium intake and its various sources with type 2 diabetes: Tehran lipid and glucose study.
    Nutr Metab (Lond). 2025;22:120.
    PubMed         Abstract available
    
    

    
    Obstet Gynecol

52. GREENBERG M, Zhu Y, Shan J, Hedderson MM, et al
    Gestational and Pregestational Diabetes Screening Changes in Early Pregnancy and Perinatal Outcomes.
    Obstet Gynecol. 2025 Oct 16. doi: 10.1097/AOG.0000000000006090.
    PubMed         Abstract available
    
    

    
    Ophthalmology

53. NISHIDA K, Katakami N, Maeno T, Nishida K, et al
    Re: Armbrust et al.: Preoperative glycemic control and acute endophthalmitis after cataract surgery in United States veterans with diabetes mellitus (Ophthalmology. 2025;132:903-910).
    Ophthalmology. 2025 Oct 16:S0161-6420(25)00560.
    PubMed        
    
    

    
    Pediatr Diabetes

54. GUNDOGDU OGUTLU OB, Cayir A, Donmez AS, Koca SB, et al
    Diabetes Insipidus as an Early Clinical Indicator of Wolfram Syndrome Type 1: Evidence From a Symptom-Based Screening Approach.
    Pediatr Diabetes. 2025;2025:8692152.
    PubMed         Abstract available
    
    

    
    PLoS One

55. KIM H, Lee SW, Lim Y, Han N, et al
    Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study.
    PLoS One. 2025;20:e0333604.
    PubMed         Abstract available
    
    
56. SU B, Cao X
    Associations across food consumption, diabetes prevalence and the environmental impacts: Evidence from China.
    PLoS One. 2025;20:e0334136.
    PubMed         Abstract available
    
    
57. KUO TJ, Huang SW, Lin HW
    Correction: Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality.
    PLoS One. 2025;20:e0334531.
    PubMed         Abstract available
    
    

    
    Retina

58. KIRIK F, Ersoz MG, Atalay F, Akbulut E, et al
    OUTER RETINAL LAYER DETERIORATION PATTERNS IN EYES WITH DIABETIC SEROUS MACULAR DETACHMENT.
    Retina. 2025 Oct 7. doi: 10.1097/IAE.0000000000004698.
    PubMed         Abstract available
    
    

    
    Transplant Proc

59. HIRAMITSU T, Himeno T, Shimamoto Y, Hasegawa Y, et al
    Perioperative Severe Complications Can Cause Pancreatic Graft Failure and Mortality in Pancreas Transplantation.
    Transplant Proc. 2025 Jun 14:S0041-1345(25)00278.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.